Researchers Design 5 GPCR-Bound Miniproteins, Advancing Drugs for Pain, Cancer and Migraine
Updated
Updated · Nature.com · May 21
Researchers Design 5 GPCR-Bound Miniproteins, Advancing Drugs for Pain, Cancer and Migraine
4 articles · Updated · Nature.com · May 21
A new Nature study reports computationally designed miniproteins that bind difficult GPCR drug targets with high affinity, potency and selectivity, including agonists for itch and pain receptors and antagonists for receptors tied to cancer, diabetes, obesity and migraine.
The team paired de novo protein design with a high-throughput receptor-diversion microscopy screen, tackling a target class long considered hard for protein agonist and antagonist design because GPCRs are membrane-embedded and conformationally dynamic.
Cryo-EM structures of 5 receptor-bound designs closely matched the computational models, providing structural evidence that the designed binders engage their targets as intended.
One designed chemokine receptor antagonist mobilized hematopoietic stem and progenitor cells in vivo at levels comparable to a clinically used drug, while producing fewer adverse effects.
Because GPCRs are among the most important drug targets in physiology and medicine, the work points to a broader route for building protein therapeutics against receptors that have been difficult to drug selectively.
Will AI-designed miniproteins make today's blockbuster drugs obsolete by being safer and more precise?
This breakthrough drug is safer than its clinical alternative. How does this AI revolution in medicine actually reach patients?
Revolutionizing GPCR Drug Discovery: AI-Engineered Miniproteins Enter Clinical Pipeline in 2026
Overview
Researchers at the University of Washington’s Institute for Protein Design, together with Skape Bio, have achieved a major breakthrough by using artificial intelligence to design miniproteins that can precisely activate or block G protein-coupled receptors (GPCRs). These AI-designed miniproteins are engineered to fit into the deep, dynamic pockets of GPCRs, overcoming challenges that have limited traditional drugs. This approach allows for highly selective activation or inhibition of GPCRs, opening new possibilities for treating diseases that were previously hard to target. The innovation marks a significant step forward in drug discovery and therapeutic development.